Trial Profile
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects ≥ 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Ivosidenib (Primary) ; Azacitidine; Azacitidine
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms AGILE
- Sponsors Agios Pharmaceuticals
- 03 Apr 2024 Planned End Date changed from 30 Jun 2024 to 30 Jun 2026.
- 12 Dec 2023 Results performing an NGS analysis of MRD responses in this study,presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 05 Dec 2023 According to a Servier media release, data from this trial will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition 2023.